[{"address1": "5858 Horton Street", "address2": "Suite 455", "city": "EmeryVille", "state": "CA", "zip": "94608", "country": "United States", "phone": "510 505 2680", "website": "https://www.4dmoleculartherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.", "fullTimeEmployees": 171, "auditRisk": 3, "boardRisk": 6, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1717200000, "maxAge": 86400, "priceHint": 2, "previousClose": 22.61, "open": 22.89, "dayLow": 22.06, "dayHigh": 23.12, "regularMarketPreviousClose": 22.61, "regularMarketOpen": 22.89, "regularMarketDayLow": 22.06, "regularMarketDayHigh": 23.12, "beta": 2.876, "forwardPE": -6.827381, "volume": 1377078, "regularMarketVolume": 1377078, "averageVolume": 558006, "averageVolume10days": 585760, "averageDailyVolume10Day": 585760, "bid": 22.92, "ask": 23.03, "bidSize": 100, "askSize": 100, "marketCap": 1186076032, "fiftyTwoWeekLow": 9.44, "fiftyTwoWeekHigh": 36.25, "priceToSalesTrailing12Months": 57.990322, "fiftyDayAverage": 24.9462, "twoHundredDayAverage": 20.60965, "currency": "USD", "enterpriseValue": 674336256, "floatShares": 30884516, "sharesOutstanding": 51703400, "sharesShort": 9646011, "sharesShortPriorMonth": 9834818, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.1866, "heldPercentInsiders": 0.03498, "heldPercentInstitutions": 1.10674, "shortRatio": 21.88, "shortPercentOfFloat": 0.1933, "impliedSharesOutstanding": 51703400, "bookValue": 11.739, "priceToBook": 1.9541699, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -104556000, "trailingEps": -2.36, "forwardEps": -3.36, "pegRatio": 0.48, "enterpriseToRevenue": 32.97, "enterpriseToEbitda": -5.786, "52WeekChange": 0.28156424, "SandP52WeekChange": 0.26238096, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "FDMT", "underlyingSymbol": "FDMT", "shortName": "4D Molecular Therapeutics, Inc.", "longName": "4D Molecular Therapeutics, Inc.", "firstTradeDateEpochUtc": 1607697000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "3c71667a-4f1e-3d28-8cb0-26ab7aa9e925", "messageBoardId": "finmb_272879653", "gmtOffSetMilliseconds": -14400000, "currentPrice": 22.94, "targetHighPrice": 82.0, "targetLowPrice": 35.0, "targetMeanPrice": 52.3, "targetMedianPrice": 45.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 525911008, "totalCashPerShare": 10.172, "ebitda": -116549000, "totalDebt": 14171000, "quickRatio": 32.062, "currentRatio": 32.652, "totalRevenue": 20453000, "debtToEquity": 2.36, "revenuePerShare": 0.473, "returnOnAssets": -0.17292999, "returnOnEquity": -0.25527, "freeCashflow": -49054624, "operatingCashflow": -76974000, "revenueGrowth": -0.906, "operatingMargins": -1362.0, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]